Royalty Pharma Research and Development Expenses 2019-2024 | RPRX

Royalty Pharma research and development expenses for the twelve months ending September 30, 2024 were $2M, a 98.04% decline year-over-year.

  • Royalty Pharma annual research and development expenses for 2023 were $0.052B, a 70.64% decline from 2022.
  • Royalty Pharma annual research and development expenses for 2022 were $0.177B, a 11.48% decline from 2021.
  • Royalty Pharma annual research and development expenses for 2021 were $0.2B, a 661.09% increase from 2020.

Royalty Pharma Research and Development Expenses 2019-2024 | RPRX

  • Royalty Pharma annual research and development expenses for 2023 were $0.052B, a 70.64% decline from 2022.
  • Royalty Pharma annual research and development expenses for 2022 were $0.177B, a 11.48% decline from 2021.
  • Royalty Pharma annual research and development expenses for 2021 were $0.2B, a 661.09% increase from 2020.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$212.2B
Blackstone (BX)$143.7B
Moody's (MCO)$87.1B
Synchrony Financial (SYF)$25.7B
Orix Corp Ads (IX)$25B
Brookfield Asset Management (BAM)$24.6B
Grupo Financiero Banorte SAB De CV (GBOOY)$19.2B
SoFi Technologies (SOFI)$16.9B
Jefferies Financial Group (JEF)$16.1B
Equitable Holdings (EQH)$14.9B
Houlihan Lokey (HLI)$13.1B
Globe Life (GL)$9.3B
Daiwa Securities Group (DSEEY)$9.2B
XP (XP)$8.7B
Brookfield Wealth Solutions (BNT)$8.5B
SouthState (SSB)$8.3B
StepStone Group (STEP)$7.7B
Jackson Financial (JXN)$7.5B
Freedom Holding (FRHC)$7.1B
Upstart Holdings (UPST)$6.8B
Lazard (LAZ)$6.5B
Blue Owl Capital (OBDC)$5.9B
Rithm Capital (RITM)$5.7B
Virtu Financial (VIRT)$5.7B
Core Scientific (CORZ)$5.1B
AXOS FINANCIAL, INC (AX)$4.8B
Euronet Worldwide (EEFT)$4.6B
PJT Partners (PJT)$3.9B
Cleanspark (CLSK)$3.8B
Community Financial System (CBU)$3.7B